The estimated Net Worth of James Blome is at least $5.91 Milione dollars as of 31 December 2020. Mr. Blome owns over 4,140 units of Calyxt Inc stock worth over $1,173,577 and over the last 6 years he sold CLXT stock worth over $247,836. In addition, he makes $4,488,350 as Chief Executive Officer e Director at Calyxt Inc.
Sign up
Mr. Blome CLXT stock SEC Form 4 insiders trading
James has made over 7 trades of the Calyxt Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,140 units of CLXT stock worth $17,264 on 31 December 2020.
The largest trade he's ever made was selling 6,397 units of Calyxt Inc stock on 29 June 2020 worth over $30,770. On average, James trades about 2,273 units every 60 days since 2018. As of 31 December 2020 he still owns at least 186,282 units of Calyxt Inc stock.
You can see the complete history of Mr. Blome stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Blome biography
James A. Blome is Chief Executive Officer, Director of the Company. Jim Blome grew up on a family corn and soybean farm in Hubbard, Iowa and a graduate of Iowa State University. Prior to joining Calyxt, Jim was the President and CEO for Bayer CropScience LP (North America). He held executive positions at Valent (Sumitomo Chemical) and Agriliance LLC before joining Bayer. Jim serves as the Chairman of CropLife America, Chairman of US Farming and Ranching Foundation, the Independent, Non-Executive Chairman of Concentric Ag Technologies, Inc. Jim is the 2013 recipient of the Henry A. Wallace Award from Iowa State University for outstanding leadership and service to agriculture. Kincannon & Reed, a leading executive search firm focused on the food, agribusiness, and biosciences sectors, assisted Calyxt
What is the salary of James Blome?
As the Chief Executive Officer e Director of Calyxt Inc, the total compensation of James Blome at Calyxt Inc is $4,488,350. There are no executives at Calyxt Inc getting paid more.
How old is James Blome?
James Blome is 57, he's been the Chief Executive Officer e Director of Calyxt Inc since 2018. There are 4 older and 9 younger executives at Calyxt Inc. The oldest executive at Calyxt Inc is Philippe Dumont, 68, who is the Independent Director.
What's James Blome's mailing address?
James's mailing address filed with the SEC is Mount Ridge Road, Roseville, Ramsey County, Minnesota, 55113-5499, United States.
Insiders trading at Calyxt Inc
Over the last 7 years, insiders at Calyxt Inc have traded over $2,578,214 worth of Calyxt Inc stock and bought 116,475 units worth $1,447,167 . The most active insiders traders include Kimberly K. Nelson, Daniel F Voytas e Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of $35,853. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth $7,200.
What does Calyxt Inc's logo look like?
Complete history of Mr. Blome stock trades at Calyxt Inc
Calyxt Inc executives and stock owners
Calyxt Inc executives and other stock owners filed with the SEC include:
-
James Blome,
Chief Executive Officer, Director -
William Koschak,
Chief Financial Officer -
Debra Frimerman,
General Counsel -
Kimberly Nelson,
Independent Director -
William F. Koschak,
Chief Financial Officer -
Dr. Travis J. Frey Ph.D.,
Chief Technology Officer -
Daniel Voytas,
Chief Scientific Officer -
Philippe Dumont,
Independent Director -
Yves Ribeill,
Chairman of the Board -
Christopher Neugent,
Independent Director -
Anna Kozicz-Stankiewicz,
Independent Director -
Jonathan Fassberg,
Independent Director -
Chris Tyson,
IR Contact Officer -
Laurent Arthaud,
Director -
Bobby Williams,
Director - Gene Editing -
Vince Restucci,
Vice President of Agronomy Services -
Sarah Reiter,
Vice President - Business Development -
Travis Frey,
Chief Technology Officer -
Keith Blanks,
Senior Vice President of Sales and Marketing -
Gerry Nuovo,
Sr. VP of Bus. Devel. -
Dr. Stephen M. Bravo,
Chief Medical Officer -
Trina Lundblad,
Director of Communications -
Debra H. Frimerman,
Gen. Counsel & Corp. Sec. -
Dr. Daniel F. Voytas Ph.D.,
Founder, Chief Science Officer & Chair of Scientific Advisory Board -
Michael Allen Carr,
Pres, CEO & Director -
Michael A. Carr,
President and CEO -
Manoj Sahoo,
Chief Commercial Officer -
Alain Godard,
Director -
Bryan W.J. Corkal,
Chief Financial Officer -
Michel Arbadji,
Director of Business Developme -
Federico A. Tripodi,
Chief Executive Officer -
Glenn R Bowers,
Vice President of Breeding -
S.A. Cellectis,
10% owner